CN106389436A - Pharmaceutical composition containing quinazolino indazole derivatives - Google Patents
Pharmaceutical composition containing quinazolino indazole derivatives Download PDFInfo
- Publication number
- CN106389436A CN106389436A CN201610761375.9A CN201610761375A CN106389436A CN 106389436 A CN106389436 A CN 106389436A CN 201610761375 A CN201610761375 A CN 201610761375A CN 106389436 A CN106389436 A CN 106389436A
- Authority
- CN
- China
- Prior art keywords
- pharmaceutical composition
- cell
- cancer
- compound
- alkyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention relates to a pharmaceutical composition containing quinazolino indazole derivatives for treating cancer. The structure of quinazolino indazole derivatives is represented by the formula (I); wherein R1 and R2 individually represent H, a halogen atom, or a C1-C6 alkyl group; and R3 represents H, a halogen atom, a C1-C6 alkyl group, or a halogenated C1-C6 alkyl group. The quinazolino indazole derivatives have a good medicinal activity of treating cancer, especially have a good curative effect on liver cancer, do not affect the normal physiological functions of normal liver cells, and thus have a good application prospect and potential in the liver cancer treatment field.
Description
Technical field
The invention provides a kind of pharmaceutical composition, more specifically, there is provided one kind comprises quinazolinone and indazole spreads out
The biological pharmaceutical composition that can be used to treating cancer, belongs to medicinal chemistry art.
Background technology
Quinazol derivative as the very important nitrogen-containing heterocycle compound of a class, be widely used in medicine, agricultural,
The industries such as chemical industry.At present, many quinazolinones medicines are widely used in actual life, such as antihypertensive prazosin,
Diuretics methaqualone etc..
As one of Quinazol derivative, quinazolinone indazole derivative is also the important nitrogenous condensed ring of a class
Compound, it has multiple specific performances, for example：
Weiguang Yang et al. (Palladium-Catalyzed Cascade Reaction of2-Amino-N '-
arylbenzohydrazides with Triethyl Orthobenzoates To Construct Indazolo[3,2-b]
Quinazolinones, J.Org.Chem., 2015,80,482-489) disclose a class indazole simultaneously [3,2-b] quinazolinone in
The synthetic method of compound and its fluorescent characteristic having.
K.Siva Kumar et al. (A new cascade reaction:concurrent construction of
Six and five membered rings leading to novel fused quinazolinones) disclose indazole
And quinazolinones can be used as phosphodiesterase 4 (PED4) inhibitor, thus can have for treating asthma, chronic pulmonary resistance
The diseases such as plug disease, and there is anti-inflammatory and bronchiectasis and other effects, there is potential medicinal usage.
As described above, disclosing some purposes of indazole quinazolinones in prior art, but these use at present
Way major part is limited only to its fluorescence property and respiratory disease therapy field, without for Other diseases especially cancer
The report of any expanded application of disease.
Content of the invention
Present inventor has performed in-depth study, after having paid substantial amounts of creative work, thus completing the present invention.
Specifically, technical scheme and content are related to a kind of comprise the available of quinazolinone indazole derivative
Carry out the pharmaceutical composition for the treatment of cancer.
In the described pharmaceutical composition of the present invention, described quinazolinone indazole derivative are the compounds of lower formula (I)：
Wherein, R1、R2It is each independently selected from H, halogen or C1-C6Alkyl；
R3Select H, halogen, C1-C6Alkyl or halo C1-C6Alkyl.
In the described pharmaceutical composition of the present invention, the implication of described halogen refers to halogen, non-exclusively for example may be used
For F, Cl, Br or I.
In the described pharmaceutical composition of the present invention, described C1-C6The implication of alkyl refers to there is the straight of 1-6 carbon atom
Chain or branched alkyl, that includes C1Alkyl, C2Alkyl, C3Alkyl, C4Alkyl, C5Alkyl or C6Alkyl, in non-limiting manner for example
Can be methyl, ethyl, n-propyl, isopropyl, normal-butyl, sec-butyl, isobutyl group, the tert-butyl group, n-pentyl, isopentyl or n-hexyl
Deng.
In the described pharmaceutical composition of the present invention, described halo C1-C6The implication of alkyl refers to by described halogen substiuted
" C defined above1-C6Alkyl ", for example, trifluoromethyl, pentafluoroethyl group, difluoromethyl, chloromethyl etc. in non-limiting manner.
In the described pharmaceutical composition of the present invention, preferably R1For H.
In the described pharmaceutical composition of the present invention, preferably R2For H.
In the described pharmaceutical composition of the present invention, preferably R3For H or halo C1-C6Alkyl.
In the described pharmaceutical composition of the present invention, preferably R1For H, R2For H and R3For halo C1-C6Alkyl.
In the described pharmaceutical composition of the present invention, most preferably R1For H, R2For H and R3For trifluoromethyl.
In the described pharmaceutical composition of the present invention, as a kind of preferably, under described quinazolinone indazole derivative are
Formula (I-1) compound：
In the described pharmaceutical composition of the present invention, described pharmaceutical composition also comprises pharmaceutically acceptable carrier, tax
Shape agent and/or auxiliary agent.
Wherein, " pharmaceutically acceptable carrier " refers to organism not caused significant stimulation also do not eliminate applied chemical combination
The carrier of the biologically active of thing and characteristic or diluent.Generally, these include patient's examining for pharmacology/toxicology aspect
Consider, and pharmaceutical chemistry man is for the physical/chemical aspect of composition, preparation, stability, patient acceptance and bioavilability
Consideration be considered acceptable characteristic and/or material.
Wherein, " excipient " or " auxiliary agent " refers to be added in pharmaceutical composition thus further helping in applying of compound
Inert substance, the example includes but is not limited to：Calcium carbonate, calcium phosphate, multiple sugared and multiple starch, cellulose derivative
(inclusion microcrystalline cellulose), gelatin, vegetable oil, polyethylene glycol, diluent, granulating agent, lubricant, binding agent, disintegrant and
Analog.
In the described pharmaceutical composition of the present invention, described cancer can be liver cancer, lung cancer, cancer of the stomach, cervical carcinoma and cancer of pancreas
In any one or arbitrarily multiple, most preferably liver cancer.
Inventor finds, the quinazolinone of formula (I) indazole derivative has good active anticancer, especially above formula
(I-1) compound is inactivated by inducing cell mitochondria and hinders Nrf2-ARE signal path, can effectively suppress HCC
The growth of Hep3B, and harmless to normal liver cell HL-7702.Also observe Caspase-3 activation, Bcl- in Hep3B cell
2 declines cause mitochondrial apoptosis, and the rise of glycoprotein V DAC1 simultaneously leads to mitochondrial membrane potential to decline, and collective effect promotes line
Plastochondria inactivates, thus causing Apoptosis.Meanwhile, stress be in path Nrf2-ARE in endogenous anti-oxidative, Nrf2 is subject to derivative
Thing affects and lowers, and NQO1 downstream is suppressed, thus direct or indirect damaging cells lead to Apoptosis.By cell
Activity test (MTT decoration method) directly illustrates that above formula (I-1) compound has obvious suppression and makees to the growth of Hep3B cell
With, and have no effect on the cytoactive of HL-7702, further demonstrate that described compound has preferable anticancer and lives to HCC
Property, can be used as potential medicines resistant to liver cancer.
In sum, the invention provides a kind of anticancer pharmaceutical composition comprising quinazolinone indazole derivative, institute
State the specific quinazolinone in composition and indazole derivative has good resisting liver cancer activity, can be used as potential anti-liver cancer drug
Thing, has a good application prospect and is worth.
Brief description
Accompanying drawing 1 is the impact vigor to HL-7702 and Hep3B natural death of cerebral cells and correlative protein expression for formula (I-1) compound
Impact.
Accompanying drawing 2A-2C is that formula (I-1) compound relies on to HL-7702 and Hep3B cell Mitochondria film potential and voltage
The impact of property anion channel 1 (VDAC1) albumen.
Accompanying drawing 3 is the impact to nuclear factor Nrf2 and downstream NQO1 protein expression for formula (I-1) compound.
Accompanying drawing 4A-4B is the expression of ARE- luciferase assay results and downstream gene.
Specific embodiment
Below by specific example, the present invention is described in detail, but the purposes of these exemplary embodiments and mesh
Be only used for enumerate the present invention, not the real protection scope of the present invention is constituted with any type of any restriction, more non-incite somebody to action this
The protection domain of invention is confined to this.
Embodiment 1：Cytotoxicity GI to different clones50
Experimental procedure：Miapaca-2 used in it is pancreatic cancer cell, Hela is human cervical carcinoma cell and Hep3B
For human liver cancer cell.Respectively by each cell in the DMEM nutrient solution life being 10% hyclone containing mass percentage content
Long, the antibiotic concentration in nutrient solution is 100 μ/ml penicillin and streptomysin 100 μ g/ml, and cell culture is to be 37 in temperature
DEG C, carbon dioxide volumetric concentration be 5% incubator in carry out.
Cell is uniformly plated on 96 orifice plates, cell density is about 5 × 103, every hole addition 200 μ l complete culture solutions,
Incubated overnight.Treat the smooth adherent growth of cell, add containing 25 μm of medicines without serum DMEM culture medium, process 24 hours.
Prepare PBS (phosphate buffer) solution of MTT so that MTT is 5 μ g/m to concentration, add in serum free medium and incubate in 37 DEG C
Educate 4 hours.Culture medium is abandoned in suction, adds 100 μ l DMSO (dimethyl sulfoxide (DMSO)) in every hole, is placed in shaking table room and rocks 20 minutes, extremely
Precipitation dissolving is completely.96 orifice plates light absorption value at 490nm is measured by ELIASA, and passes through software processing.
Experimental result：Measure formula (I-1) compound by cell activity assays (MTT decoration method) thin to different clones
Cellular toxicity GI50(process cell optical density and drop to cell concentration when 50% with respect to untreated cell optical density, SEM is flat
All deviations), result see table 1.
Table 1
It can be seen that, (I-1) compound is larger to cancer cell toxicity, especially notable with Hela cell, is secondly Hep3B
Cell, minimum to Miapaca cytotoxicity.Entirety sees that (I-1) compound all has different degrees of toxic action to cancer cell, its
In to Hep3B highly significant, be suitable as medicines resistant to liver cancer.
Embodiment 2：Impact to HL-7702 and Hep3B Apoptosis and correlative protein expression
Experimental procedure：HL-7702 used in it is Human normal hepatocyte, the culture of condition of culture and above-mentioned Hep3B
Unanimously.
With compound treatment Hep3B and HL-7702 cell 24 hours, pancreatin digests and collects cell.PBS punching with precooling
Wash three times, add 100 μ l cell pyrolysis liquid RIPA to crack 30 minutes on ice, period vortex oscillation frequently.4 DEG C of collected after centrifugation
Supernatant simultaneously measures protein concentration using bradford method.After calculating suitable sample concentration, protein sample is added proper ratio
Sample-loading buffer, and high-temperature denatured 5 minutes.Configuration separation gel mass content is 10%, concentration glue mass content is 5% poly- third
Acrylamide gel, loading runs glue, and electric current 40mA, time are 2 hours.By protein delivery to PVP film, electric current 110mA, the time is 90
Minute.After film room temperature is closed 2 hours, TBST flushes three times, and adds corresponding antibody incubation overnight, TBST flushes three times,
Anti- 2 hours of incubation corresponding two, TBST flushes three times post-exposure colour developing, and using software processing analysis.
Experimental result is shown in Fig. 1, and the ordinate of wherein four width figures is " relative ratios of apoptotic proteins/internal reference albumen ", with
And " * " represents P<0.05 and " * * " expression P<0.01.
Apoptotic generation and development can be summarized as inducing cell apoptosis, adjust apoptosis and effect execution, in this rank
Section Mitochondria electron transport chain plays an important role in apoptotic initial period.Caspase-3 is apoptosis execution rank
The key point of section, once activate further inducing cell apoptosis.Additionally, Bcl-2 controls multiple apoptogenes, and it is subject to simultaneously
Caspase-3 regulation and control and impact.
It can be seen from figure 1 that formula (I-1) compound can cause caspase-3 activation in Hep3B cell.And pass through and standard
Condition contrasts, find its by 35kDa activate into 17kDa about small fragment, and then the expression of Bcl-2 also reduces simultaneously.This enters
One step explanation, formula (I-1) compound can induce Hep3B Apoptosis, and HL-7702 cell is then injured less.
Embodiment 3：To HL-7702 and Hep3B cell Mitochondria film potential and voltage dependence anion channel 1
(VDAC1) impact of albumen
Experimental procedure：Using JC-1 cell apoptosis detection kit, measure the mitochondrial membrane potential (MMP) of cell.JC=1
As mitochondrial membrane potential specificity fluorescent probe, there are two kinds of forms, being in during electronegative potential is monomer, transmitting green fluorescence；
It is in during high potential and is collected as complex, launch red fluorescence.Complete mitochondrial membrane potential is in high potential, once and electronics
Damaging occurs in chain, i.e. apoptosis phenomenon, and mitochondrial membrane potential will reduce.The change in fluorescence of JC-1 can be considered line grain
One index of body membrane stage.
By HL-7702 cell and Hep3B cell after drug-treated 24 hours, trypsin digestion cell is simultaneously collected.PBS rinses
Twice, be incubated 30 minutes with 37 DEG C of lucifuges of JC-1 stain working solution, then use the wash buffer of precooling twice, after be suspended in slow
Rush and in liquid, adopt flow cytometry analysis.Setting passage is respectively FL1 (FITC, green fluorescence) and FL2 (PE, red fluorescence) and enters
Row detection, adopts modfit software analysis data afterwards.
Voltage dependence anion channel 1 (VDAC1) albumen is as the crucial egg in the electron transport chain on mitochondrial membrane
In vain, can be extracted using the same procedure in embodiment 2.
Through flow cytometer (result is shown in Fig. 2A -2B) detection, and VDAC1 albumen/internal reference albumen relative ratios' histogram
(see Fig. 2 C, wherein " * " expression P<0.05), result is shown in Fig. 2A -2C.
Wherein, in Fig. 2 C, the ordinate of two width figures is " VDAC1 albumen/internal reference albumen relative ratios ".
Mitochondrial function plays a significant role in cell survival with apoptosis.Voltage dependence anion channel 1 (VDAC1)
Albumen is a kind of multifunctional protein, is primarily targeted for mitochondrial outer membrane, adjusts series of physiological and pathological activity, such as intracellular Ca2+
Ionic equilibrium, energetic supersession and Apoptosis.For further determining that whether (I-1) compound can lead to line with inducing cell apoptosis
Plastochondria damages, and we have studied mitochondrial membrane potential situation of change and VDAC1 expression.Understand from Fig. 2A -2B, normal
In liver cell HL-7702, after (I-1) compound treatment, red fluorescence is 79.4%.Meanwhile, in HCC Hep3B,
After (I-1) compound treatment, green fluorescence is 81.6%.It can be seen that, (I-1) compound is for the mitochondrial membrane of Hep3B cell
Current potential impact is more prominent, significantly reduces mitochondrial membrane potential, illustrates that compound has higher murder by poisoning for HCC
Effect.
Additionally, compared with normal cell, after (I-1) compound treatment, the expression of VDAC1 albumen in Hep3B cell
Substantially rise, this Novel presentation is it may be possible to the reason lead to mitochondrial membrane potential to damage.
Embodiment 4：Impact to nuclear factor Nrf2 and downstream NQO1 protein expression
Experimental procedure：Extract albumen and western blot is identical with example 2.
Cell, through compound treatment 24 hours, collects cell extraction Protein Detection changes of contents, and result is shown in Fig. 3, wherein, institute
The ordinate having four width figures is " relative ratios of Nrf2 (NQO1) albumen/internal reference albumen ", and " * " represents P<0.05.
For illustrating compound mediated apoptotic molecular mechanism, we have studied (I-1) compound and pass through Nrf2-ARE
The effect that signal path plays in HL-7702 cell and Hep3B cell.Nrf2-ARE signal path is used for adapting to aoxidize answering
Swash, there are numerous antioxidant genes downstream, including NQO1, HO-1, Gclc etc..In the cancer cell of normal shape body, Nrf2 egg
Bai great Liang activates, and leads to cancer cell to have the oxidation resistance properties more higher than normal cell.Fig. 3 shows, through (I-1) compound treatment
Afterwards, in Hep3B cell, the expression of Nrf2 albumen is decreased obviously, the protein content in even below HL-7702.Compound (I-1)
While compound is notable to Hep3B toxic action, the impact to HL-7702 cell is less.Additionally, downstream gene NQO1 also shows
Write and decline, this phenomenon, more serious damage stress be produced system to Hep3B cellular oxidation, further result in Apoptosis.
Embodiment 5：ARE- luciferase assay results and the expression of downstream gene
Experimental procedure：By HL-7702 cell and Hep3B cell with 3 × 104The density in/hole is seeded to 24 orifice plates, treats cell
Bed board about 70% is transfected.Plasmid is purchased from addgene, i.e. pARE-luc (for detecting the activation of ARE signal path) and pRL-
SV40-N (carries renilla luc gene, for detecting transfection efficiency).Plasmid is bought according to green skies biotechnology research
Plasmid little take out kit extract, -80 DEG C store for future use.Using liposome transfection plasmid, according to 3:1 ratio, transfects respectively
PARE-luc plasmid and pRL-SV40-N plasmid.Transfection is inhaled after 6 hours and is abandoned nutrient solution, adds the culture containing 25 μm of compounds
Base, is processed 2 hours, 6 hours and 24 hours respectively.According to arrangement of time, trypsin digestion cell is simultaneously collected, using luc fluorescein
Enzyme reagent kit detects, and analyze data.
Extract the mRNA collecting cell.Extracted using Trizol reagent, concretely comprised the following steps：Collect cell and use PBS
Flush three times, after centrifugation, outwell supernatant, add 500 μ l Trizol reagent in cell precipitation, vortex cell is separated into slender
Born of the same parents, room temperature stands 5 minutes.4 DEG C of centrifugations, draw supernatant to new pipe, add 200 μ l chloroforms, turn upside down to mixing, room temperature is quiet
It is centrifuged after putting 2 minutes.In careful absorption stratified liquid, the superiors, to new pipe, add 500 μ l isopropanols, are centrifuged after turning upside down
Abandon supernatant, ttom of pipe is mRNA.The mass percent concentration adding precooling is 75% ethanol purge mRNA, after centrifugation
Volatilization ethanol, adds ddH2O, measures mRNA concentration.It is stored in -80 DEG C, for follow-up RT-PCR and Q-PCR experiment.
MRNA is cDNA according to reverse transcription reagent box reverse transcription, after measuring concentration, according to 5 μ l Mix, 3 μ l H2O、1μl
The ratio of cDNA and 0.5 μ l primer carries out RT-PCR experiment.According to 10 μ l SYBR, 6 μ l H2O, 2 μ l cDNA and 1 μ l primer
Ratio carries out Q-PCR experiment.
Investigate the impact to Nrf2 oxidative stress signal path in HL-7702 and Hep3B cell for (I-1) compound；Real
When quantitative fluorescent PCR measure the expression of Nrf2-ARE signal path downstream gene (HO-1, NQO1, Gclc), result is shown in figure
(" * " represents P to 4A-4B<0.05 and " * * " expression P<0.01.).In wherein Fig. 4 A, the ordinate of two width figures is " luciferase list
The relative value of unit's expression ", in Fig. 4 B, the ordinate of three width figures is " light relative density ".
Understand from Fig. 4 A, after (I-1) compound treatment, activating in various degree occurs in cell Nrf2-ARE signal path
Phenomenon.Process 2 hours and 6 little constantly the Nrf2-ARE signal path of Hep3B cell is in holddown, and HL-7702 cell
Nrf2-ARE signal path unaffected, or even also in the 6 little signs that slightly rising constantly occurs.But 24 little constantly, can
Energy process time is long, the reason such as (I-1) compound concentration decline, and the impact of (I-1) compound on intracellular gradually decreases,
The holddown elementary solution of Hep3B cell removes, and wherein ARE-luc fluorescence substantially rises.
Meanwhile, also have detected the situation of change of mRNA, after discovery (I-1) compound treatment, the impact to Hep3B is larger, its
In especially downstream gene NQO1 and GCLC.The reduction of mRNA level in-site, directly results in the expression (see Fig. 4 B) of albumen.Due to can
Know, (I-1) compound has considerable influence to Hep3B, they can suppress oxidative stress path signal to transmit, and reduces Nrf2 egg
White expression, thus affecting the expression of downstream antioxidant genes, and then leads to Hep3B Apoptosis.
In sum, can clearly be found out by above-mentioned all embodiments, quinazolinone of the present invention indazole derivative
There is the pharmaceutically active of good treating cancer, especially to liver cancer, there is good therapeutic effect, and it is thin not affect normal hepatocytes
The normal physiological function of born of the same parents, thus have a good application prospect and potentiality in liver cancer treatment field.
It should be appreciated that the purposes of these embodiments is merely to illustrate the present invention and is not intended to limit the protection model of the present invention
Enclose.Additionally, it will also be appreciated that after the technology contents having read the present invention, those skilled in the art can make each to the present invention
Plant and change, change and/or modification, all these equivalent form of value equally falls within the guarantor that the application appended claims are limited
Within the scope of shield.
Claims (9)
1. a kind of pharmaceutical composition of the treating cancer comprising quinazolinone indazole derivative, described quinazolinone indazole spreads out
Biology is the compound of lower formula (I)：
Wherein, R1、R2It is each independently selected from H, halogen or C1-C6Alkyl；
R3Select H, halogen, C1-C6Alkyl or halo C1-C6Alkyl.
2. pharmaceutical composition as claimed in claim 1 it is characterised in that：Described R1For H.
3. pharmaceutical composition as claimed in claim 1 or 2 it is characterised in that：Described R2For H.
4. the pharmaceutical composition as described in any one of claim 1-3 it is characterised in that：Described R3For H or halo C1-C6Alkyl.
5. the pharmaceutical composition as described in any one of claim 1-4 it is characterised in that：Described R1For H, R2For H and R3For trifluoro
Methyl.
6. the pharmaceutical composition as described in any one of claim 1-5 it is characterised in that：Described quinazolinone indazole derivative
It is following formula (I-1) compound：
7. the pharmaceutical composition as described in any one of claim 1-6 it is characterised in that：Described pharmaceutical composition also comprises pharmacy
Upper acceptable carrier, excipient and/or auxiliary agent.
8. the pharmaceutical composition as described in any one of claim 1-7 it is characterised in that：Described cancer is liver cancer, lung cancer, stomach
Cancer, any one in cervical carcinoma and cancer of pancreas or arbitrarily multiple.
9. the pharmaceutical composition as described in any one of claim 1-8 it is characterised in that：Described cancer is liver cancer.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610761375.9A CN106389436A (en) | 2016-08-29 | 2016-08-29 | Pharmaceutical composition containing quinazolino indazole derivatives |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610761375.9A CN106389436A (en) | 2016-08-29 | 2016-08-29 | Pharmaceutical composition containing quinazolino indazole derivatives |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN106389436A true CN106389436A (en) | 2017-02-15 |
Family
ID=58002731
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201610761375.9A Pending CN106389436A (en) | 2016-08-29 | 2016-08-29 | Pharmaceutical composition containing quinazolino indazole derivatives |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN106389436A (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN113480537A (en) * | 2021-06-18 | 2021-10-08 | 广西师范大学 | Quinazolinone [2,3-a ] carboline derivative and preparation method and application thereof |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103980280A (en) * | 2014-04-22 | 2014-08-13 | 温州大学 | Method for synthesizing quinazolino indazole derivatives under acidic condition |
-
2016
- 2016-08-29 CN CN201610761375.9A patent/CN106389436A/en active Pending
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103980280A (en) * | 2014-04-22 | 2014-08-13 | 温州大学 | Method for synthesizing quinazolino indazole derivatives under acidic condition |
Non-Patent Citations (3)
| Title |
|---|
| JEEN LEE: "Cyclic AMP induces inhibition of cyclin A expression and growth arrest in human hepatoma cells", 《BIOCHIMICA ET BIOPHYSICA》 * |
| K. SIVA KUMAR: "A new cascade reaction: concurrent construction of six and five membered rings leading to novel fused quinazolinones", 《ORGANIC&BIOMOLECULAR CHEMISTRY》 * |
| PETROS X.E. MOURATIDIS: "Antiproliferative Effects of CC-8062 and CC-8075 in Pancreatic Cancer Cells", 《PANCREAS》 * |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN113480537A (en) * | 2021-06-18 | 2021-10-08 | 广西师范大学 | Quinazolinone [2,3-a ] carboline derivative and preparation method and application thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Klein et al. | The roles and regulation of MDM2 and MDMX: it is not just about p53 | |
| Liu et al. | Two novel glycosides from the fruits of Morinda citrifolia (noni) inhibit AP-1 transactivation and cell transformation in the mouse epidermal JB6 cell line | |
| Ma et al. | High glucose induces autophagy in podocytes | |
| Singh et al. | Defining the momiome: Promiscuous information transfer by mobile mitochondria and the mitochondrial genome | |
| Lai et al. | Long noncoding RNA MIAT promotes non-small cell lung cancer proliferation and metastasis through MMP9 activation | |
| Dung et al. | PP2A mediates diosmin p53 activation to block HA22T cell proliferation and tumor growth in xenografted nude mice through PI3K–Akt–MDM2 signaling suppression | |
| Sarill et al. | The aryl hydrocarbon receptor suppresses cigarette-smoke-induced oxidative stress in association with dioxin response element (DRE)-independent regulation of sulfiredoxin 1 | |
| Jiang et al. | Bufalin induces cell cycle arrest and apoptosis in gallbladder carcinoma cells | |
| Martin et al. | NUPR1 and its potential role in cancer and pathological conditions | |
| Tian et al. | Upregulation of DAPK contributes to homocysteine-induced endothelial apoptosis via the modulation of Bcl2/Bax and activation of caspase 3 | |
| Li et al. | Epigenome and transcriptome study of moringa isothiocyanate in mouse kidney mesangial cells induced by high glucose, a potential model for diabetic-induced nephropathy | |
| Ning et al. | Low-and high-dose hydrogen peroxide regulation of transcription factor NF-E2-related factor 2 | |
| Han et al. | ZEB1 directly inhibits GPX4 transcription contributing to ROS accumulation in breast cancer cells | |
| Hou et al. | The NuRD complex-mediated p21 suppression facilitates chemoresistance in BRCA-proficient breast cancer | |
| Zheng et al. | Baicalin inhibiting cerebral ischemia/hypoxia-induced neuronal apoptosis via MRTF-A-mediated transactivity | |
| Piszczatowska et al. | Inhibition of NADPH oxidases activity by diphenyleneiodonium chloride as a mechanism of senescence induction in human cancer cells | |
| Zhang et al. | Upregulation of miR‑33b promotes endometriosis via inhibition of Wnt/β‑catenin signaling and ZEB1 expression | |
| Shao et al. | Phenethyl isothiocyanate suppresses the metastasis of ovarian cancer associated with the inhibition of CRM1-mediated nuclear export and mTOR-STAT3 pathway | |
| Cao et al. | Physalin B induces G2/M cell cycle arrest and apoptosis in A549 human non-small-cell lung cancer cells by altering mitochondrial function | |
| Guan et al. | Resveratrol inhibits hypoxia-induced proliferation and migration of pulmonary artery vascular smooth muscle cells by inhibiting the phosphoinositide 3-kinase/protein kinase B signaling pathway | |
| Bao et al. | Dynamic equilibrium of endogenous selenium nanoparticles in selenite-exposed cancer cells: a deep insight into the interaction between endogenous SeNPs and proteins | |
| de Silanes et al. | Acquisition of resistance to butyrate enhances survival after stress and induces malignancy of human colon carcinoma cells | |
| Zhu et al. | The SMYD3-MTHFD1L-formate metabolic regulatory axis mediates mitophagy to inhibit M1 polarization in macrophages | |
| Ni et al. | m6A Modification—Association with Oxidative Stress and Implications on Eye Diseases | |
| Jash et al. | MicroRNA-29b modulates β-secretase activity in SH-SY5Y cell line and diabetic mouse brain |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20170215 |